Becton Dickinson & Co (BDX) stock price, news and key stats

Price

Last close as of Sep 16, 2026. Delayed data; not a live quote.

Previous close

$185.92

Open

$185.18

Day range

$181.29 – $186.23

Volume

1.7M

About Becton Dickinson & Co

Latest BDX news

• Improved Neubauer Chamber Slides Market Outlook to 2035
  Market Outlook · Sep 9, 2026

  The Neubauer chamber slides market is projected to experience significant growth through 2035, driven by advancements in laboratory technology and an increasing demand for precise cell counting in various research and clinical applications. The rising prevalence of chronic diseases and the growing emphasis on early diagnosis are key factors contributing to this positive outlook. As healthcare providers and research institutions continue to prioritize accurate and efficient diagnostic tools, the Neubauer chamber slides are expected to remain a staple in laboratories worldwide. Market analysts anticipate that the introduction of innovative designs and materials will enhance the functionality and usability of Neubauer chamber slides, further boosting their adoption. Additionally, the expansion of biotechnology and pharmaceutical sectors, particularly in emerging markets, is likely to create new opportunities for manufacturers. As competition intensifies, companies may focus on product differentiation and strategic partnerships to capture a larger share of the market. Investors and stakeholders should monitor these trends closely, as the growth of the Neubauer chamber slides market could have broader implications for the laboratory equipment sector. Increased demand may lead to heightened investments in research and development, ultimately fostering technological advancements that benefit the healthcare industry as a whole.

• Pharma Microbiology Testing Kits Market Outlook Signals Expansion To $11.97 Billion Through 2030
  Market Outlook · Aug 24, 2026

  The pharma microbiology testing kits market is poised for significant growth, with projections indicating an increase from $7.26 billion in 2025 to approximately $11.97 billion by 2030. This represents a robust compound annual growth rate (CAGR) of 10.8%, driven primarily by advancements in the biopharmaceutical pipeline and a rising preference for rapid testing technologies. The anticipated growth reflects the increasing demand for effective microbiological testing in drug development and quality control processes. Key factors contributing to this expansion include the ongoing evolution of the biopharmaceutical sector, which is seeing a surge in new drug candidates and therapies requiring rigorous microbiological testing. Additionally, the adoption of rapid testing methods is enhancing the efficiency and accuracy of microbial assessments, further propelling market growth. As regulatory standards continue to tighten, pharmaceutical companies are likely to invest more heavily in microbiology testing solutions, positioning themselves to meet compliance requirements while ensuring product safety. Market implications are significant, as this growth trajectory may attract increased investment in research and development within the microbiology testing sector. Companies that innovate and adapt to the changing landscape of pharmaceutical testing will likely gain a competitive edge, while those that fail to keep pace may struggle to maintain market share. Overall, the pharma microbiology testing kits market is set to play a crucial role in the broader pharmaceutical industry, supporting the development of safe and effective medical products.

• Platelet Aggregation Devices Market Outlook Signals Expansion To $2.93 Billion Through 2030
  Market Outlook · Aug 24, 2026

  The platelet aggregation devices market is poised for significant growth, with projections indicating an expansion from $1.04 billion in 2025 to approximately $2.93 billion by 2030. This represents a remarkable compound annual growth rate (CAGR) of 25.4% over the next several years. The surge in market value is attributed to increasing demand for advanced diagnostic tools in cardiovascular diseases, as well as rising awareness regarding the importance of platelet function testing in various medical settings. Market analysts anticipate that innovations in technology and product development will further drive this expansion. As healthcare providers increasingly adopt point-of-care testing and personalized medicine approaches, the need for efficient and accurate platelet aggregation devices will become more pronounced. This trend is expected to attract investments from both established players and new entrants in the medical device sector, potentially leading to heightened competition and advancements in product offerings. The implications for investors and stakeholders in the healthcare market are significant. With a robust growth trajectory forecasted, companies operating in this space may see enhanced revenue opportunities and improved market positioning. However, the rapid pace of innovation also necessitates that firms remain agile and responsive to evolving regulatory standards and technological advancements to maintain their competitive edge.

• Medical Low Value Consumables Market Outlook Signals Expansion To $17.36 Billion Through 2030
  Market Outlook · Aug 17, 2026

  The global medical low value consumables market is projected to expand significantly, reaching approximately $17.37 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.7%. This growth is largely attributed to the rising prevalence of chronic diseases and an increasing demand for continuous medical interventions. As healthcare systems worldwide adapt to these trends, the market for low-cost consumable items is expected to play a crucial role in supporting ongoing patient care and treatment. Major players in the medical supplies sector, including Medtronic plc, Cardinal Health, and Becton, Dickinson and Company, are well-positioned to benefit from this growth trajectory. The broader medical supplies market is also on an upward trend, projected to grow from $198.17 billion in 2026 to $318.77 billion by 2031, reflecting a robust CAGR of 9.97%. This indicates a healthy demand for medical products, which is likely to drive innovation and investment in the sector. As the healthcare landscape evolves, particularly in Europe, there is a shift towards industrial maturity, moving away from the fragmented market of the early 2020s. This transition is expected to enhance operational efficiencies and improve the delivery of care, further bolstering the demand for low value consumables. With the convergence of artificial intelligence and value-based care models, the medical consumables market is set to experience transformative changes that will shape healthcare delivery in the coming years.

• Lateral Flow Reader Market Outlook Signals Expansion To $2.44 Billion Through 2030
  Market Outlook · Aug 13, 2026

  The lateral flow reader market is projected to expand significantly, reaching an estimated value of $2.44 billion by 2030, according to recent analysis from Market Outlook. This growth is driven by increasing demand for rapid diagnostic testing across various sectors, including healthcare, food safety, and environmental monitoring. The rise in infectious diseases and the ongoing emphasis on point-of-care testing are key factors contributing to the market's expansion. Technological advancements in lateral flow assay development are also expected to enhance the accuracy and efficiency of these devices, further driving adoption. As healthcare systems worldwide continue to prioritize quick and reliable diagnostic solutions, companies in the lateral flow reader space are likely to see increased investment and innovation. This trend may lead to heightened competition, as new entrants and established players alike strive to capture market share in a rapidly evolving landscape. Market implications suggest that stakeholders should closely monitor regulatory developments and technological innovations that could impact product offerings and market dynamics. Additionally, the growing emphasis on personalized medicine and home testing solutions may present new opportunities for lateral flow reader manufacturers, potentially reshaping the competitive landscape in the coming years.

• BD’s (NYSE:BDX) Q1 CY2026 Sales Beat Estimates
  Earnings · May 7, 2026

  Becton, Dickinson and Company (NYSE:BDX) reported fiscal 2026 first‑quarter revenue of $4.71 billion, a 5.2 % year‑over‑year increase that surpassed analysts’ expectations. Non‑GAAP earnings per share came in at $2.90, 4.5 % above the consensus estimate of $2.78. The company also reiterated its full‑year 2026 revenue growth guidance, signaling confidence in continued demand for its medical technology products. The results were driven by solid performance across BD’s core segments, including sterile supplies, diagnostics, and animal health, as well as a modest uptick in its emerging‑markets sales. Management highlighted ongoing investment in digital health and supply‑chain resilience, which it expects to sustain margin expansion. The company’s ability to deliver above‑forecast earnings amid a competitive landscape reinforces its position as a leading supplier of critical medical devices and supplies. Market participants reacted positively, with BD shares rising roughly 2 % in after‑hours trading, reflecting investor approval of the earnings beat and the firm’s reaffirmed guidance. The uptick may also support broader medical‑technology indices, as the company’s performance underscores resilience in the sector despite supply‑chain pressures and regulatory uncertainties. Investors will likely monitor BD’s quarterly guidance and product pipeline for further signals on long‑term growth prospects.

Index membership

• S&P 500 · Health Care

Related Health Care stocks

• AAgilent Technologies
• ABBVAbbVie
• ABTAbbott Laboratories
• ALGNAlign Technology
• AMGNAmgen
• BAXBaxter International
• BIIBBiogen
• BMYBristol Myers Squibb